Pfho.Pk
PFHO.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.
Business. PFHO.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
PFHO.PK operates in the healthcare facilities and services industry, focusing on biotechnology, and generates revenue primarily through its services and equipment offerings.
PFHO.PK maintains a strong liquidity position, as evidenced by a current ratio of 34.45, indicating a significant buffer of current assets over current liabilities. The company has no long-term debt, and its total liabilities are minimal at $388,600, while total equity stands at $13,074,850. This capital structure suggests a low financial leverage and a strong equity base, which supports its operational flexibility and resilience.
In terms of profitability, PFHO.PK demonstrates a return on equity (ROE) of 10.61% and a return on assets (ROA) of 10.31%. These figures are indicative of efficient asset utilization and strong profitability relative to its equity base. The company's operating income of $1,001,040 and net income of $1,387,650 further underscore its ability to generate profits from its operations.
PFHO.PK's revenue is concentrated within its primary business segment, which is biotechnology, and there is no disclosed geographic diversification in the financial data provided. This concentration may expose the company to specific market risks, particularly if demand for its services or products in this segment fluctuates.
The company's growth trajectory is supported by its strong cash flow generation, with an operating cash flow of $1,160,780 and a free cash flow of $1,351,350. These figures suggest that PFHO.PK has the financial capacity to reinvest in its operations or return value to shareholders. However, the capital expenditure of -$23,280 indicates a minimal investment in new assets, which may limit future growth unless offset by organic expansion or strategic acquisitions.
Risk factors for PFHO.PK are currently low, with no immediate filing-based liquidity or dilution flags detected. The company's low debt-to-equity ratio of 0.0 and strong equity position reduce the likelihood of financial distress. Additionally, the absence of dilution potential and the low probability of near-term dilution further support the company's stable capital structure.
Recent events, as reflected in the financial data, show a consistent performance with no significant negative developments reported. The company's financial health appears to be stable, with no recent filings or transcripts indicating operational or financial distress.
- PFHO.PK has a strong liquidity position with a current ratio of 34.45 and no long-term debt.
- The company demonstrates high profitability with a return on equity of 10.61% and a return on assets of 10.31%.
- PFHO.PK's revenue is concentrated in its biotechnology segment, which may pose market-specific risks.
- The company generates significant free cash flow, indicating strong operational efficiency and financial flexibility.
- **margin_outlook_rationale**: The company's strong gross profit margin and operating income suggest a stable and improving margin outlook.
- **rd_outlook_rationale**: There is no specific data provided on R&D spending, but the company's focus on biotechnology implies ongoing investment in research and development.
- **capex_outlook_rationale**: The minimal capital expenditure indicates a conservative approach to asset investment, which may limit future growth unless offset by other strategies.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- Return On Assetsnet_income / total_assets
- PFHO.PK Market data — financials · 2026-05-28
Ownership & reference
Insider activity
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Return on assets (FY 2025-12-31): 10.3%Derived (calculated)
- Return on equity (FY 2025-12-31): 10.6%Derived (calculated)
- Net margin (FY 2025-12-31): 20.7%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 8.3%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 11.9%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 10.7%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): 17.4%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 71.9%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): 57.0%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 57.1%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 57.1%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 4.7%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2024-12-31): 154.9%Derived (calculated)
- Current ratio (FY 2025-12-31): 34.45xDerived (calculated)
- Operating cash flow (annual): USD 1.16MSEC XBRL filing
- Shareholders' equity (annual): USD 13.07MSEC XBRL filing
- Cash & equivalents (annual): USD 2.17MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 0SEC XBRL filing
- Operating income (annual): USD 1MSEC XBRL filing
- EPS (diluted) (annual): USD-PER-SHARES 0SEC XBRL filing
- Interest expense (annual): USD 1.52KSEC XBRL filing
- Current liabilities (annual): USD 388.6KSEC XBRL filing
- Current assets (annual): USD 13.39MSEC XBRL filing
- Shares outstanding (annual): 12.8MSEC XBRL filing